What the number means
“503B” refers to a section of the federal Food, Drug, and Cosmetic Act. A 503B facility — the law calls it an outsourcing facility — is a compounder that chooses to register with the FDA so it can make medications in bulk and ship them to healthcare providers, rather than filling one prescription at a time. In return for that flexibility, it agrees to operate under Current Good Manufacturing Practice (CGMP): the same category of quality controls and inspections applied to drug manufacturers.
Why it matters for GLP-1s
The 503B distinction became central to the GLP-1 story during the semaglutide and tirzepatide shortages, when compounded versions filled the gap and a large share flowed through 503B facilities. For a patient weighing a compounded option, “Is it made in a 503B facility?” is one of the more useful quality questions to ask — CGMP oversight is a real signal.
It’s also why the category is volatile: when the FDA changes what outsourcing facilities are permitted to compound, supply can shift quickly. Its sibling, the 503A pharmacy, compounds patient-by-patient under state boards instead. Which one is behind a product shapes both its quality controls and its availability — worth checking when you compare providers.